<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00625040</url>
  </required_header>
  <id_info>
    <org_study_id>GB-INK</org_study_id>
    <nct_id>NCT00625040</nct_id>
  </id_info>
  <brief_title>Incretin Physiology and Beta-cell Function Before and After Weight-loss</brief_title>
  <official_title>Incretin Physiology and Beta-cell Function Before and After Weight-loss - Effects of Long-term Weight Loss Following Laparoscopic Adjustable Gastric Banding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Foundation for the Study of Diabetes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the impact of laparoscopic adjustable gastric banding (LAGB) on beta-cell
      function, insulin sensitivity, incretin function, postprandial secretion of incretin hormones
      (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) in
      morbidly obese patients and to describe the pathophysiological mechanisms involved in the
      amelioration of glucose homeostasis during long-term weight loss.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Morbid obesity represents a serious health issue in Western countries, with a rising
      incidence and a strong association with increased mortality and serious co-morbidities, such
      as diabetes. Surgical interventions, such as laparoscopic gastric banding have been developed
      with the aim of providing a laparoscopic placed device that is safe and effective in
      generating substantial weight loss. By investigation of the incretin effect, the secretion of
      GIP and GLP-1, the insulin response and sensitivity and the beta-cell responsiveness to
      glucose in 10 obese patients without type 2 diabetes before and after laparoscopic gastric
      banding the aim of this project is describe the pathophysiological mechanisms involved in the
      amelioration of glucose homeostasis during long-term weight loss.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not enough patients in the follow-up period
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incretin effect before and one year after gastric banding in obese patients without diabetes</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GLP-1 and GIP response curves</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>Obese patients without diabetes with a Body Mass Index &gt; 37 kg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate</intervention_name>
    <description>OGTT: The test is performed with 50 g of glucose deluded in 300 ml water
Isoglycemic iv. clamp: Iv. glucose infusion mimicking the glucose response curves from the OGTT
Liquid Meal test: The test is performed with 100g of formula milk deluded in 300 ml. water
Gastric Emptying Rate: Paracetamol absorption test.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      p-glucose, p-glucagon, p-GLP1, p-GIP, p-cpeptid, p-insulin, p-paracetamol, buffy coat, urine,
      whole blood sampels
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The cases and controls are recruited from The Bariatric Clinic at Glostrup Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasians without type 2 diabetes mellitus

          -  Normal OGTT (75 g of glucose) according to WHO's criteria

          -  Patients fulfilling the criteria for laparoscopic gastric banding

          -  Normal Hemoglobin

          -  Informed consent

        Exclusion Criteria:

          -  Liver disease (ALAT &gt; 2 x normal level)

          -  Nephropathy (s-creatinin &gt; 130 ÂµM or albuminuria)

          -  Relatives (parents/siblings) with T2DM

          -  Medical treatment witch cannot be stopped for 12 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katrine Bagge Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glostrup University Hospital, Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filip K Knop, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gentofte Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steen Larsen, MD, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Glostrup University Hospital, Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Juul Holst, MD,DMSc</last_name>
    <role>Study Director</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Viggo Kristensen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Glostrup University Hospital, Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glostrup Hospital</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2008</study_first_submitted>
  <study_first_submitted_qc>February 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2008</study_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Glostrup University Hospital, Copenhagen</investigator_affiliation>
    <investigator_full_name>Katrine Bagge Hansen</investigator_full_name>
    <investigator_title>MD, Ph.d</investigator_title>
  </responsible_party>
  <keyword>Incretin effect</keyword>
  <keyword>Gastric banding</keyword>
  <keyword>Glucagon</keyword>
  <keyword>Glucagon-Like Peptide 1</keyword>
  <keyword>Gastric Inhibitory Peptide</keyword>
  <keyword>Glucose Intestinal Peptide</keyword>
  <keyword>Insulin</keyword>
  <keyword>C-peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

